Most Read Articles
Stephen Padilla, 3 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

6 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.

Adherence, persistence to oral anticoagulants in first year of treatment suboptimal

08 Nov 2019

Adherence and persistence to oral anticoagulants (OACs) the first year of treatment appear to be relatively low across drugs, a study has found.

Researchers looked at time trends at individual and system levels, as well as the risk factors for and associations between adherence and persistence, using data from the UK primary care EHR (The Health Information Network 2011–2016).

The analysis included 36,652 individuals with incident atrial fibrillation, cardiovascular comorbidities (median CHA2DS2VASc [Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65–74 years, Sex category], 3) and polypharmacy (median number of drugs, 6).

Adherence rates at 1 year after treatment initiation were 55.2 percent (95 percent confidence interval [CI], 54.6–55.7) for all OACs, 51.2 percent (95 percent CI, 50.6–51.8) for vitamin K antagonist (VKA), 66.5 percent (95 percent CI, 63.7–69.2) for dabigatran, 63.1 percent (95 percent CI, 61.8–64.4) for rivaroxaban and 64.7 percent (95 percent CI, 63.2–66.1) for apixaban.

One-year persistence rates were 65.9 percent (95 percent CI, 65.4–66.5) for all OACs, 63.4 percent (95 percent CI, 62.8–64.0) for VKA, 61.4 percent (95 percent CI, 58.3–64.2) for dabigatran, 72.3 percent (95 percent CI, 70.9–73.7) for rivaroxaban and 78.7 percent (95 percent CI, 77.1–80.1) for apixaban.

Nonadherence and nonpersistence increased over time at individual and system levels. Increasing comorbidity was associated with a lower likelihood of nonadherence and nonpersistence across all OACs.

Overall, the rate of ‘primary nonadherence’ (stopping after first prescription) was 3.5 percent, ‘nonadherent nonpersistence’ 26.5 percent and ‘persistent adherence’ 40.2 percent. These rates varied across OACs.

The present data may help to better understand the determinants of adherence and persistence, and to design and target interventions to improve adherence and persistence together across drugs, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

6 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.